In Vivo Imaging of Methionine Aminopeptidase II for Prostate Cancer Risk Stratification.

ABSTRACT: Prostate cancer is one of the most common malignancies worldwide, yet limited tools exist for prognostic risk stratification of the disease. Identification of new biomarkers representing intrinsic features of malignant transformation and development of prognostic imaging technologies are critical for improving treatment decisions and patient survival. In this study, we analyzed radical prostatectomy specimens from 422 patients with localized disease to define the expression pattern of methionine aminopeptidase II (MetAP2), a cytosolic metalloprotease that has been identified as a druggable target in cancer. MetAP2 was highly expressed in 54% of low-grade and 59% of high-grade cancers. Elevated levels of MetAP2 at diagnosis were associated with shorter time to recurrence. Controlled self-as

SUBMITTER: Xie J 

PROVIDER: S-EPMC8137584 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature